Fate Therapeutics, Inc.FATENASDAQ
LOADING
|||
Operating Income Growth Under Pressure
Trending lower, above historical average.
Left:
||||
Year-over-year operating income growth rate
Latest
6.04%
↑ 183% above average
Average (39q)
-7.23%
Historical baseline
Range
High:55.62%
Low:-118.82%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 6.04% |
| Q2 2025 | 10.45% |
| Q1 2025 | 33.15% |
| Q4 2024 | -17.89% |
| Q3 2024 | -16.18% |
| Q2 2024 | 11.72% |
| Q1 2024 | -6.23% |
| Q4 2023 | 6.25% |
| Q3 2023 | 18.04% |
| Q2 2023 | -118.82% |
| Q1 2023 | 55.62% |
| Q4 2022 | 25.43% |
| Q3 2022 | -3.95% |
| Q2 2022 | -11.61% |
| Q1 2022 | -7.33% |
| Q4 2021 | -27.02% |
| Q3 2021 | -16.77% |
| Q2 2021 | -1.23% |
| Q1 2021 | -38.36% |
| Q4 2020 | -6.07% |
| Q3 2020 | -9.68% |
| Q2 2020 | 16.77% |
| Q1 2020 | -18.62% |
| Q4 2019 | -7.22% |
| Q3 2019 | -12.60% |
| Q2 2019 | -17.79% |
| Q1 2019 | -22.13% |
| Q4 2018 | -0.29% |
| Q3 2018 | 14.86% |
| Q2 2018 | -39.50% |
| Q1 2018 | -14.78% |
| Q4 2017 | -18.41% |
| Q3 2017 | -8.05% |
| Q2 2017 | 4.02% |
| Q1 2017 | -30.27% |
| Q4 2016 | 8.76% |
| Q3 2016 | -4.81% |
| Q2 2016 | -1.11% |
| Q1 2016 | -14.53% |
| Q4 2015 | -9.23% |